论著康柏西普联合玻璃体切除术治疗增殖期糖尿病性视网膜病变的临床疗效∗王会艳胡鹏蒋丽娟黄英(邵阳学院附属第一医院,湖南邵阳４２２０００)[摘要]【目的】探讨康柏西普联合玻璃体切除术(PPV)治疗增殖期糖尿病性视网膜病变(PDR)的临床疗效.【方法】选取２０２０年８月至２０２２年１０月在本院就诊的４６例(５０眼)PDR患者作为研究对象,按照随机数字表法分为观察组和对照组,每组２３例(２５眼).对照组患者给予单纯２３GPPV治疗,观察组患者给予康柏西普联合２３GPPV治疗.比较两组患者手术时间及术中和术后情况.【结果】观察组手术时间显著短于对照组(t＝２．４７,P＜０．０５);观察组术后最佳矫正视力(BCVA)度数高于对照组(P＜０．０５);因医源性视网膜裂孔、视网膜脱落实行的硅油填充率低于对照组(P＜０．０５).【结论】康柏西普联合２３GPPV治疗PDR患者,可有效缩短手术时间,改善患者术后视力,降低并发症发生率.[关键词]糖尿病视网膜病变/并发症;糖尿病,２型/并发症;玻璃体切除术;血管生成抑制剂/治疗应用ClinicalEffectsofConberceptinCombinationwithVitrectomyforProliferativeDiabeticRetiＧnopathyWANGHuiyan,HUPeng,JIANGLijuan,etal(ShaoyangFirstHospital,AffiliatedtoShaoyangUniversity,ShaoyangHunan４２２０００)[Abstract]【Objective】Toinvestigatetheclinicaleffectofconberceptcombinedwithvitrectomy(PPV)inthetreatmentofproliferativediabeticretinopathy(PDR)．【Methods】Totally４６patients(５０eyes)withPDR,whovisitedourhospitalfromAugust２０２０toOctober２０２２,wereselectedasthestudysubjects,andtheywererandomlydividedintotwogroups．Therewere２３patients(２５eyes)intheconventionalgroupwhoweretreatedwith２３GPPValoneand２３patients(２５eyes)inthestudygroupwhoweretreatedwithconberceptＧassisted２３GPPV．PostoperativefollowＧupincludedacomparisonofsurgicaldurationandchangesinintraopＧerativeandpostoperativeconditionsbetweenthetwogroups．【Results】Theaveragesurgicaldurationinthestudygroupwassignificantlylowerthanthatintheconventionalgroup(t＝２．４７,P＜０．０５)．Postoperatively,thebestcorrectedvisualacuity(BCVA)inthestudygroupwashigherthanthatintheconventionalgroup．Additionally,theratesofiatrogenicretinalbreakandretinaldetachmenttreatedwithsili...
